Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
R1 Therapeutics expands Series A financing to $80.5 million with new investment from Samsara BioCapital. The funds will advance their Phase 2b program for hyperphosphatemia in patients with chronic kidney disease.
Amount Raised
$80.5 Million
Round Type
Series A
Investors
Description
R1 Therapeutics, a biopharmaceutical company focused on kidney disease therapies, has expanded its Series A financing to $80.5 million. This expansion includes new investment from Samsara BioCapital, joining other notable investors. The raised funds will support the development of R1's lead asset, AP306, in a global Phase 2b trial. The trial aims to address hyperphosphatemia in patients on dialysis, with topline data expected in early 2027.
Fundz sees it the moment R1 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansR1 Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.